RE: Revised Revenue7 Dec 2021 20:36
Don’t forget we are still awaiting new products by the end of Q4.
That should be in a matter of weeks .
As far as we know final tweaks may be made to our saliva based lateral flow test that we are developing with a partner .
The delay was on procuring enough materials to make the LFT on a big enough scale and who IS the partner ?
Remember GM said this test could add “significant revenues to the company “
Could it be a big pharma with enough clout to procure the necessary materials and assays and we may well be off to the races .
Combine the above with the increasing demand for world class PCR tests and a resolution with DHSC and we could be back in double digits before year end .
Keep the faith all genuine holders .
PathFlow® SARS-CoV-2 Antigen is a professional and home use LFT for the detection of SARS-CoV-2 antigens using non-invasive anterior nasal swab samples to provide a result in approximately 15 minutes. Novacyt has been working with a partner to develop this test, which is able to detect the virus regardless of current known mutations. The Company intends to launch the test as CE-IVD before the end of Q2 2021 and expects it to complement Novacyt’s established position in COVID-19 PCR testing. As the market for COVID-19 testing continues to develop, the Directors believe this product could add significant revenues for Novacyt.
Expansion of the genesig® COVID-19 PCR portfolio
Following an emerging need in some countries, Novacyt has launched a CE-IVD genesig® COVID-19 three-gene target test for use with nasopharyngeal, oropharyngeal and saliva sample types. This key extension to the genesig® COVID-19 portfolio, alongside the one- gene and two-gene tests, is expected to be critical for use in airport test and release programmes to and from certain countries.
Sign In
Follow the stocks
